

< 5.1.2e @soton.ac.uk>, 5.1.2e < 5.1.2e @phe.gov.uk>, 5.1.2e
 < 5.1.2e @ntlworld.com>
Cc: 5.1.2e < 5.1.2e @phe.gov.uk>, 5.1.2e < 5.1.2e @phe.gov.uk>, 5.1.2e
 5.1.2e < 5.1.2e @phe.gov.uk>, 5.1.2e < 5.1.2e @phe.gov.uk>, 5.1.2e < 5.1.2e @phe.gov.uk>,
 5.1.2e < 5.1.2e @phe.gov.uk>, 5.1.2e < 5.1.2e @phe.gov.uk>

Subject: RE: Data from Moderna and AZ trials

This email from 5.1.2e @uhbw.nhs.uk originates from outside Imperial. Do not click on links and attachments unless you recognise the sender. If you trust the sender, add them to your [safe senders list](#) to disable email stamping for this address.

Thanks for the update 5.1.2e

Regards

5.1.2e

From: 5.1.2e 5.1.2e 5.1.2e @nuh.nhs.uk]
Sent: 27 January 2021 11:20
To: 5.1.2e @lshtm.ac.uk; 5.1.2e @ftcon.co.uk; 5.1.2e @wales.nhs.uk; 5.1.2e ; 5.1.2e ; 5.1.2e ;
 5.1.2e ; 5.1.2e ; 5.1.2e @nhslothian.scot.nhs.uk; 5.1.2e ; 5.1.2e @warwick.ac.uk';
 5.1.2e @rug.nl; 5.1.2e @nhs.net'; 5.1.2e @gmail.com; 5.1.2e @soton.ac.uk'; 5.1.2e ; 5.1.2e ;
Cc: 5.1.2e ; 5.1.2e ; 5.1.2e e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e
Subject: Data from Moderna and AZ trials

Dear All,

We have heard back from Moderna regarding the additional analyses shared with JCVI in confidence on efficacy following the first dose. They have requested that those data **remain In Confidence** please. They are looking into a further publication that includes those data.

Regarding the AZ data, a further manuscript has been submitted to Lancet. Andy P expects a fast review process.

Therefore, although we do not have permission to share the latest data we have seen at JCVI, the good news is that hopefully, in a short time, there will be peer-reviewed publications containing data on first dose efficacy over an extended period.

Best wishes,

5.1.2e

From: 5.1.2e [5.1.2e @phe.gov.uk]
Sent: 26 January 2021 16:12
To: 5.1.2e ; 5.1.2e @ftcon.co.uk; 5.1.2e @wales.nhs.uk; 5.1.2e ; 5.1.2e @lshtm.ac.uk'; 5.1.2e
 5.1.2e ; 5.1.2e @rivm.nl'; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e ;
 5.1.2e ; 5.1.2e @nhslothian.scot.nhs.uk; 5.1.2e ; 5.1.2e @warwick.ac.uk';
 5.1.2e @rug.nl; 5.1.2e @nhs.net'; 5.1.2e @gmail.com; 5.1.2e @soton.ac.uk'; 5.1.2e ; 5.1.2e ;
Cc: 5.1.2e ; 5.1.2e ; 5.1.2e e ; 5.1.2e ; 5.1.2e ; 5.1.2e ; 5.1.2e
Subject: RE: COVID-19 vaccine first dose prioritisation modelling

This is now published at

[Prioritising the first COVID-19 vaccine dose: JCVI statement - GOV.UK \(www.gov.uk\)](#)

Kind regards

5.1.2e

5.1.2e

5.1.2e

Immunisation Service
National Infection Service
Public Health England

Email: 5.1.2e [@phe.gov.uk](mailto:5.1.2e@phe.gov.uk)

Tel: 020 5.1.2e

www.gov.uk/phe Follow us on Twitter @PHE_uk

Protecting and improving the nation's health

5.1.2e

5.1.2e

5.1.2e

5.1.2e

buiten verzoek

5.1.2e

Tracking ID: A63E1CB2-B9DF-F205-B6FE-E7FC12DC12EE - Wed Jan 27 11:19:36 2021

If you have received this email in error please notify the sender.

Tracking ID: 92519211-B9E1-2005-A76D-7A60A6F38E13 - Wed Jan 27 12:44:04 2021